

North Ottawa Community Health System
 Cumulative Antimicrobial Susceptibility Summary Jan. 1, 2018 - Dec. 31, 2018
 BioMerieux Vitek® 2 MIC Methodology

NON-URINE SOURCE

Organism	# Isolates	%Susceptible																											
		Amoxicillin/Clav	Ampicillin	Aztreonam	Cefazolin	Cefepime	Cefotaxime	Ceftriaxone	Ciprofloxacin	Clindamycin	Ertapenem	Erythromycin	Gentamicin	Gentamicin(synergy)	Imipenem	Levofloxacin	Linezolid	Meropenem	Moxifloxacin	Oxacillin	Penicillin	Pip/Tazobactam	Quinup/Dalfo	Rifampin	streptomycin (synergy)	Tetracycline	Tigecycline	T/S	Vancomycin
<i>Coagulase Negative Staph</i>	26 ¹	*	*	*	*	*	*	*	85	46	*	38	100	*	*	85	100	*	88	69	0	*	100	100	*	85	100	85	100
<i>Enterococcus faecalis</i>	36	*	100	*	*	*	*	*	86	*	*	14	*	81	*	86	94	*	*	*	100	*	0	*	81	31	100	*	100
<i>Escherichia coli</i>	44	91	61	91	93	95	*	95	77	*	100	*	98	*	100	77	*	100	*	*	*	95	*	*	55	*	80	*	
<i>Pseudomonas aeruginosa</i>	25 ¹	0	0	*	0	100	*	0	88	*	*	*	96	*	96	84	*	100	*	*	*	96	*	*	0	*	0	*	
<i>Staphylococcus aureus</i>	191	*	*	*	*	*	*	*	73	79	*	52	98	*	*	75	100	*	92	65	*	*	100	99	*	95	100	100	100
<i>Methicillin Resistant Staph aureus</i>	67	*	*	*	*	*	*	*	49	73	*	16	99	*	*	48	100	*	82	0	*	*	*	99	*	97	100	100	100
<i>Methicillin Susceptible Staph aureus</i>	124	*	*	*	*	*	*	*	86	82	*	71	98	*	*	90	100	*	97	100	*	*	100	100	*	94	100	100	100
<i>Streptococcus agalactiae</i>	19 ¹	*	100	*	*	*	100	100	58	*	47	*	*	*	95	100	*	100	*	100	*	*	*	*	26	100	100	100	
<i>Streptococcus pneumoniae</i> ²	7 ¹	*	*	*	*	*	#	#	71	*	29	*	*	*	86	100	*	100	*	#	*	*	*	*	57	100	71	100	
<i>Str. Pneumo-meningitis</i>	7 ¹	*	*	*	*	*	71	71	*	*	*	*	*	*	*	*	*	*	*	*	29	*	*	*	*	*	*	*	*
<i>Str. Pneumo-nonmeningitis</i>	7 ¹	*	*	*	*	*	100	100	*	*	*	*	*	*	*	*	*	*	*	*	100	*	*	*	*	*	*	*	*

URINE SOURCE

Organism	# Isolates	%Susceptible																										
		Amoxicillin/Clav	Ampicillin	Aztreonam	Cefazolin	Cefepime	Cefotaxime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin	Gentamicin(synergy)	Imipenem	Levofloxacin	Linezolid	Meropenem	Moxifloxacin	Nitrofurantoin	Oxacillin	Penicillin	Pip/Tazobactam	Quinup/Dalfo	Rifampin	streptomycin (synergy)	Tetracycline	Tigecycline	T/S	Vancomycin
<i>Coagulase negative staph</i>	78	*	*	*	*	*	*	*	55	*	99	*	*	55	100	*	67	97	38	0	*	100	100	*	92	100	76	100
<i>Enterobacter cloacae complex</i>	40	0	*	100	0	93	*	78	98	93	98	*	93	98	*	100	*	53	*	*	75	*	*	*	100	*	93	*
<i>Enterococcus faecalis</i>	96	*	100	*	*	*	*	*	74	*	*	77	*	77	89	*	*	100	*	100	*	0	*	87	28	100	*	99
<i>Escherichia coli</i>	886	83	59	95	91	95	*	95	83	100	92	*	100	83	*	100	*	97	*	*	98	*	*	*	79	*	80	*
<i>ESBL-producing E Coli</i>	44	56	0	0	0	2	*	0	11	98	43	*	98	11	*	100	*	91	*	*	93	*	*	*	33	*	52	*
<i>Klebsiella pneumoniae</i>	157	97	0	94	95	96	*	96	97	99	99	*	99	98	*	100	*	32	*	*	97	*	*	*	82	*	94	*
<i>Proteus mirabilis</i>	103	100	79	94	92	97	*	97	66	100	95	*	93	68	*	100	*	0	*	*	100	*	*	*	0	*	68	*
<i>Pseudomonas aeruginosa</i>	50	0	0	*	0	96	*	0	84	*	96	*	92	76	*	91	*	0	*	*	98	*	*	*	0	*	0	*
<i>Staphylococcus aureus</i>	39	*	*	*	*	*	*	*	41	*	95	*	*	41	100	*	62	100	49	3	*	100	97	*	87	100	100	100
<i>Methicillin Resistant Staph aureus</i>	20 ¹	*	*	*	*	*	*	*	5	*	95	*	*	5	100	*	40	100	0	*	*	*	95	*	90	100	100	100
<i>Methicillin Susceptible Staph aureus</i>	19 ¹	*	*	*	*	*	*	*	79	*	95	*	*	79	100	*	84	100	100	*	*	100	100	*	84	100	100	100
<i>Streptococcus agalactiae</i>	12 ¹	*	100	*	*	*	100	100	*	*	*	*	*	92	100	*	100	*	*	100	*	*	*	*	25	100	100	100

*Drug not tested or drug not indicated

Breakpoints differ based on diagnosis

¹less than desirable # of isolates for statistical validity

²represents only those isolates which screen Intermediate or Resistant to oxacillin